Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CEST
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON DICKINSON AND CO
08/16 BECTON DICKINSON AND : Prescription error elimination co MedAware raises $8m
08/16 INSIDER TRADING ACTIVITY BECTON, DIC : BDX) – Insider Sold 6,149 shares of..
08/15 INSIDER TRADING ACTIVITY BECTON, DIC : BDX) – EVP Sold 7,463 shares of Sto..
08/15 BECTON DICKINSON AND : BD Expands Suite of Blood Culture Offerings with New BD B..
08/11 BECTON, DICKINSON AND COMPANY (NYSE : BDX) Files An 8-K Departure of Directors o..
08/11 BECTON DICKINSON & CO : Change in Directors or Principal Officers (form 8-K)
08/11 INSIDER TRADING ACTIVITY BECTON, DIC : BDX) – Insider Sold 9,283 shares of..
08/10 INSIDER TRADING ACTIVITY BECTON, DIC : BDX) – Insider Sold 5,971 shares of..
08/10 BECTON DICKINSON AND : Patent Issued for Syringe Housing to Facilitate Medicatio..
08/03 BECTON DICKINSON AND : Patent Issued for Density Phase Separation Device (USPTO ..
More news
News from SeekingAlpha
08/09 DIVIDEND ARISTOCRATS : Separate The Wheat From The Chaff
08/08 Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q2 ..
08/07 Dividend Champions In The Making
08/07 Vanguard Brings You Healthy Returns With Less Volatility
08/07 How To Plan For Retirement At 45 With Dividend Stocks
Financials ($)
Sales 2017 12 071 M
EBIT 2017 2 821 M
Net income 2017 1 169 M
Debt 2017 8 213 M
Yield 2017 1,43%
P/E ratio 2017 34,47
P/E ratio 2018 25,14
EV / Sales 2017 4,48x
EV / Sales 2018 4,26x
Capitalization 45 829 M
Chart BECTON DICKINSON AND CO
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Technical analysis trends BECTON DICKINSON AND CO
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 218 $
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas Polen President
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Bertram L. Scott Independent Director
Sector and Competitors